Tumor-specific immune responses and biomarkers in pediatric patients with high-risk Hodgkin lymphoma.

Saved in:
Bibliographic Details
Title: Tumor-specific immune responses and biomarkers in pediatric patients with high-risk Hodgkin lymphoma.
Authors: Toner K; Center for Cancer and Immunology Research Children's National Hospital; and Department of Pediatrics, George Washington University School of Medicine and Health Sciences, Washington, DC., Renfro LA; Division of Biostatistics, University of Southern California and Children's Oncology Group, Los Angeles, CA., Dave H; Center for Cancer and Immunology Research Children's National Hospital; and Department of Pediatrics, George Washington University School of Medicine and Health Sciences, Washington, DC., Pezzella G; Center for Cancer and Immunology Research Children's National Hospital; and Department of Pediatrics, George Washington University School of Medicine and Health Sciences, Washington, DC., Pei Q; Department of Biostatistics, University of Florida, Gainesville, FL., Giulino-Roth L; Department of Pediatrics, Weill Cornell Medical College, New York, NY., Horton T; Department of Pediatrics, Texas Children's Hospital, Baylor College of Medicine, Houston, TX., Keller FG; Aflac Cancer and Blood Disorders Center of Children's Healthcare of Atlanta/Department of Pediatrics, Emory University School of Medicine, Atlanta, GA., Kelly KM; Roswell Park Comprehensive Cancer Center/Department of Pediatrics, University at Buffalo Jacobs School of Medicine and Biomedical Sciences, Buffalo, NY., Castellino SM; Aflac Cancer and Blood Disorders Center of Children's Healthcare of Atlanta/Department of Pediatrics, Emory University School of Medicine, Atlanta, GA., Bollard CM; Center for Cancer and Immunology Research Children's National Hospital; and Department of Pediatrics, George Washington University School of Medicine and Health Sciences, Washington, DC.
Source: Blood advances [Blood Adv] 2026 Jan 13; Vol. 10 (1), pp. 183-191.
Publication Type: Journal Article; Randomized Controlled Trial; Clinical Trial, Phase III
Journal Info: Publisher: American Society of Hematology Country of Publication: United States NLM ID: 101698425 Publication Model: Print Cited Medium: Internet ISSN: 2473-9537 (Electronic) Linking ISSN: 24739529 NLM ISO Abbreviation: Blood Adv Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:2473-9537
DOI:10.1182/bloodadvances.2025016797